Movatterモバイル変換

[0]ホーム
URL:

MX353143B - Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. - Google Patents

Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.

Info

Publication number
MX353143B
MX353143BMX2013009662AMX2013009662AMX353143BMX 353143 BMX353143 BMX 353143BMX 2013009662 AMX2013009662 AMX 2013009662AMX 2013009662 AMX2013009662 AMX 2013009662AMX 353143 BMX353143 BMX 353143B
Authority
MX
Mexico
Prior art keywords
methods
biological markers
cell antagonists
predicting response
patients
Prior art date
Application number
MX2013009662A
Other languages
English (en)
Other versions
MX2013009662A (es
Inventor
Timothy W Behrens
Kasia Owczarczyk
Michael J Townsend
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech IncfiledCriticalGenentech Inc
Publication of MX2013009662ApublicationCriticalpatent/MX2013009662A/es
Publication of MX353143BpublicationCriticalpatent/MX353143B/es

Links

Classifications

Landscapes

Abstract

La presente invención se refiere a marcadores biológicos que pronostican la respuesta de pacientes antagonistas de células B. También se proporcionan métodos para utilizar estos marcadores biológicos. Además, se proporcionan métodos para identificar pacientes que sufren de una enfermedad autoinmune, e.g., artritis reumatoide, que probablemente no responderán a antagonistas de células-B, al igual que métodos para tratar a dichos pacientes. También se proporcionan métodos para seleccionar agentes terapéuticos para tratar a dichos pacientes.
MX2013009662A2011-02-282012-02-27Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.MX353143B (es)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US201161447518P2011-02-282011-02-28
US201161527525P2011-08-252011-08-25
PCT/US2012/026774WO2012118750A2 (en)2011-02-282012-02-27Biological markers and methods for predicting response to b-cell antagonists

Publications (2)

Publication NumberPublication Date
MX2013009662A MX2013009662A (es)2014-02-11
MX353143Btrue MX353143B (es)2017-12-20

Family

ID=46758440

Family Applications (1)

Application NumberTitlePriority DateFiling Date
MX2013009662AMX353143B (es)2011-02-282012-02-27Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.

Country Status (10)

CountryLink
US (2)US20140154247A1 (es)
EP (1)EP2680884B1 (es)
JP (1)JP6271254B2 (es)
KR (1)KR20140022815A (es)
CN (1)CN103502472B (es)
BR (1)BR112013021725A2 (es)
CA (1)CA2827859A1 (es)
MX (1)MX353143B (es)
RU (1)RU2013140975A (es)
WO (1)WO2012118750A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
ES2672640T3 (es)2003-11-052018-06-15Roche Glycart AgMoléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
CA2675625C (en)2007-01-232016-09-13Shinshu UniversityChronic rejection inhibitor
WO2009148148A1 (ja)2008-06-052009-12-10国立がんセンター総長が代表する日本国神経浸潤抑制剤
TWI440469B (zh)2008-09-262014-06-11Chugai Pharmaceutical Co LtdImproved antibody molecules
JOP20210044A1 (ar)2010-12-302017-06-16Takeda Pharmaceuticals Coالأجسام المضادة لـ cd38
EP2680884B1 (en)2011-02-282018-01-17F. Hoffmann-La Roche AGBiological markers and methods for predicting response to b-cell antagonists
EP2701699B1 (en)2011-04-282019-10-16The Broad Institute, Inc.Inhibitors of histone deacetylase
US9790184B2 (en)2012-07-272017-10-17The Broad Institute, Inc.Inhibitors of histone deacetylase
EP2951586A1 (en)*2013-01-312015-12-09The University of BirminghamBiomarkers of autoimmune and/or chronic diseases associated with joint inflammation
EP3009518B1 (en)*2013-06-112020-08-12National Center of Neurology and PsychiatryMethod for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
WO2015066640A1 (en)*2013-11-012015-05-07The Research Institute At Nationwide Children's HospitalKit and method for identifying individual responsiveness to steroid therapy of nephrotic syndrome
WO2015132163A1 (en)*2014-03-032015-09-11Assistance Publique - Hôpitaux De ParisA method for predicting the responsiveness a patient to a treatment with an anti-cd20 antibody
GB201412736D0 (en)*2014-07-172014-09-03Univ London Queen MaryMethod
WO2016136933A1 (ja)2015-02-272016-09-01中外製薬株式会社Ｉｌ－６関連疾患治療用組成物
WO2016186154A1 (ja)2015-05-192016-11-24国立研究開発法人国立精神・神経医療研究センター多発性硬化症（ｍｓ）患者の新規治療適用判断方法
WO2017055326A1 (en)*2015-09-292017-04-06INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055320A1 (en)*2015-09-292017-04-06INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055325A1 (en)*2015-09-292017-04-06INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for quantifying the population of nk cells in a tissue sample
WO2017055319A1 (en)*2015-09-292017-04-06INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for quantifying the population of b cells in a tissue sample
US11613586B2 (en)2016-07-152023-03-28Takeda Pharmaceutical Company LimitedMethods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
CN109963865A (zh)*2016-07-192019-07-02阿雷特发现公司用于检测和治疗肥大细胞活性相关病症的生物标记
WO2018175863A1 (en)2017-03-242018-09-27Genentech, Inc.Methods of treating autoimmune and inflammatory diseases
JP7185884B2 (ja)2017-05-022022-12-08国立研究開発法人国立精神・神経医療研究センターＩｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US10474681B1 (en)*2017-09-262019-11-12Microsoft Technology Licensing, LlcFiltering mapped datasets
EP3698808B1 (en)2017-10-202025-01-01Hyogo College Of MedicineAnti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US20200277669A1 (en)*2017-11-152020-09-03The Translational Genomics Research InstituteBiomarker proxy tests and methods for standard blood chemistry tests
WO2019140322A1 (en)2018-01-122019-07-18KDAc Therapeutics, Inc.Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
EP4502182A2 (en)2018-01-242025-02-05Genentech, Inc.Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
WO2019241158A1 (en)*2018-06-112019-12-19Univerity Of WashingtonCompositions and methods for treating inflammatory diseases
EP3820500A4 (en)*2018-07-132022-04-13Teqla Therapeutics, Inc. USE OF BCL6 INHIBITORS TO TREAT AUTOIMMUNE DISEASES
CN114555610A (zh)2019-05-202022-05-27麻省理工学院硼酸酯前药及其用途
CA3179208A1 (en)*2020-04-092021-10-14Laboratory Corporation Of America HoldingsMethods of predicting disease progression in rheumatoid arthritis
CN112669929B (zh)*2020-12-302021-08-03深圳大学克罗恩病英夫利昔单抗药效预测方法及终端设备
GB202116748D0 (en)*2021-11-192022-01-05Univ London Queen MaryMethod for treating rheumatoid arthritis

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
IL85035A0 (en)1987-01-081988-06-30Int Genetic EngPolynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en)1988-10-121988-11-16Medical Res CouncilProduction of antibodies
SG48759A1 (en)1990-01-122002-07-23Abgenix IncGeneration of xenogenic antibodies
US5633425A (en)1990-08-291997-05-27Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)1990-08-291997-08-26Genpharm International Inc.Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)1990-08-291997-04-29Genpharm International, Inc.Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en)1990-08-291992-03-30Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)1990-08-291996-08-13Genpharm International, Inc.Ransgenic non-human animals for producing heterologous antibodies
WO1992022653A1 (en)1991-06-141992-12-23Genentech, Inc.Method for making humanized antibodies
US5736137A (en)1992-11-131998-04-07Idec Pharmaceuticals CorporationTherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en)1993-05-211996-01-16Dana-Farber Cancer Institute, Inc.Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5595721A (en)1993-09-161997-01-21Coulter Pharmaceutical, Inc.Radioimmunotherapy of lymphoma using anti-CD20
KR20050085971A (ko)1995-04-272005-08-29아브게닉스, 인크.면역화된 제노마우스 유래의 인간 항체
WO1996034096A1 (en)1995-04-281996-10-31Abgenix, Inc.Human antibodies derived from immunized xenomice
JP3904238B2 (ja)1996-03-202007-04-11イムノメディクス， インコーポレイテッドグリコシル化されたヒト化ｂ細胞特異的抗体
JP2001503263A (ja)1996-10-252001-03-13ヒューマン ジノーム サイエンシーズ，インコーポレイテッドニュートロカインα
DK0942968T3 (da)1996-12-032008-06-23Amgen Fremont IncFuldt humane antistoffer, der binder EGFR
AU5705898A (en)1996-12-171998-07-15Schering CorporationMammalian cell surface antigens; related reagents
US6183744B1 (en)1997-03-242001-02-06Immunomedics, Inc.Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2232743A1 (en)1997-04-021998-10-02Smithkline Beecham CorporationA tnf homologue, tl5
PL339740A1 (en)1997-09-122001-01-02BiogenKay - a novel immune system protein
AU2093499A (en)1997-12-301999-07-19Chiron CorporationMembers of tnf and tnfr families
PT1068241E (pt)1998-04-022007-11-19Genentech IncVariantes de anticorpos e respectivos fragmentos
US6194551B1 (en)1998-04-022001-02-27Genentech, Inc.Polypeptide variants
WO2000040716A2 (en)1999-01-072000-07-13Zymogenetics, Inc.Soluble receptor br43x2 and methods of using them for therapy
US6737056B1 (en)1999-01-152004-05-18Genentech, Inc.Polypeptide variants with altered effector function
PL209786B1 (pl)1999-01-152011-10-31Genentech IncPrzeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
EP1194167B1 (en)1999-06-092009-08-19Immunomedics, Inc.Immunotherapy of autoimmune disorders using antibodies which target b-cells
NZ517782A (en)1999-08-172004-01-30Biogen IncA beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease
DE10041402A1 (de)2000-08-232002-03-14Morphochem AgNeue Verbindungen, die Faktor Xa-Aktivität inhibieren
CA2408617A1 (en)2000-05-122001-11-22Amgen Inc.Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
PT2281843T (pt)2000-06-162017-01-02Human Genome Sciences IncAnticorpos que se ligam imunoespecificamente a blys
DE60140773D1 (de)2000-08-182010-01-21Dyax CorpPolypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
UA83458C2 (uk)2000-09-182008-07-25Байоджен Айдек Ма Інк.Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
ATE432986T1 (de)2000-11-072009-06-15Zymogenetics IncMenschlicher rezeptor für tumor necrosis factor
EP2301971A1 (en)2001-02-202011-03-30ZymoGenetics, L.L.C.Antibodies that bind both BCMA and TACI
NZ529267A (en)2001-05-112006-05-26Amgen IncPeptides and related molecules that bind to tall-1
US7321026B2 (en)2001-06-272008-01-22Skytech Technology LimitedFramework-patched immunoglobulins
US20050070689A1 (en)2001-08-032005-03-31Genentech, Inc.Taci and br3 polypeptides and uses thereof
US7256015B2 (en)2001-09-212007-08-14Amgen Inc.TALL-1 receptor molecules and uses thereof
US7825089B2 (en)2001-10-242010-11-02National Jewish HealthThree-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto
RU2004127458A (ru)2002-02-142005-10-27Иммуномедикс, Инк. (Us)Анти-cd20 антитела, их гибридные белки и способы их использования
EP1476120B1 (en)2002-02-212010-09-29Duke UniversityTreatment methods using anti-cd22 antibodies
GB0210121D0 (en)2002-05-022002-06-12Celltech R&D LtdBiological products
US7258221B2 (en)2002-07-182007-08-21Fabio Perini S.P.A.Storage unit for elongated products
US7217797B2 (en)2002-10-152007-05-15Pdl Biopharma, Inc.Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4662473B2 (ja)2002-10-172011-03-30ゲンマブ エー／エスＣｄ２０に対するヒトモノクローナル抗体
UA89350C2 (uk)2002-12-162010-01-25Дженентек, Інк.Гуманізоване антитіло, що зв'язує людський cd20
US20050163775A1 (en)2003-06-052005-07-28Genentech, Inc.Combination therapy for B cell disorders
WO2005000351A2 (en)2003-06-052005-01-06Genentech, Inc.Combination therapy for b cell disorders
SI1631313T1 (sl)*2003-06-052015-06-30Genentech, Inc.Kombinirana terapija za B-celične motnje
CA2568336A1 (en)2004-06-042005-12-22Genentech, Inc.Method for treating lupus
CN101087807A (zh)2004-10-052007-12-12健泰科生物技术公司治疗血管炎的方法
AU2006259583A1 (en)2005-06-132006-12-28The Regents Of The University Of MichiganCompositions and methods for treating and diagnosing cancer
ZA200801354B (en)2005-08-092009-08-26Ares Trading SaMethods for treating B-cell malignancies using TACI-lg fusion molecule
WO2007038501A2 (en)2005-09-272007-04-05The Feinstein Institute For Medical ResearchRheumatoid arthritis markers
EP2005279A2 (en)2006-03-152008-12-24Koninklijke Philips Electronics N.V.Remote control pointing technology with roll detection
EP1857559A1 (en)2006-05-162007-11-21INSERM (Institut National de la Santé et de la Recherche Médicale)A method for predicting responsiveness to TNF alpha blocking agents
WO2008156494A1 (en)2006-11-032008-12-24The Johns Hopkins UniversityUse of high-dose oxazaphosphorine drugs in combination with monoclonal antibodies for treating immune disorders
CA2668955A1 (en)2006-11-092008-05-15Institut National De La Sante Et De La Recherche Medicale (Inserm)Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
WO2008104608A1 (en)2007-03-012008-09-04Universite Catholique De LouvainMethod for the determination and the classification of rheumatic conditions
US20090204489A1 (en)*2007-04-022009-08-13Genentech, Inc.Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2008132176A2 (en)2007-04-272008-11-06Universite Catholique De LouvainMethod for evaluating the response of an individual to tnf blocking therapy
EP2617837A3 (en)2007-06-082013-10-23Biogen Idec MA Inc.Biomarkers for predicting anti-TNF responsiveness or non-responsiveness
WO2009036283A2 (en)*2007-09-142009-03-19The Uab Research FoundationDifferential diagnosis of b-cell chronic lymphocytic leukemia
KR101620642B1 (ko)*2007-11-072016-05-12제넨테크, 인크.항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
ES2351456B1 (es)*2009-06-242011-11-28Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebronMetodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b
CA2772929A1 (en)*2009-09-032011-03-11Genentech, Inc.Methods for treating, diagnosing, and monitoring rheumatoid arthritis
EP2680884B1 (en)2011-02-282018-01-17F. Hoffmann-La Roche AGBiological markers and methods for predicting response to b-cell antagonists

Also Published As

Publication numberPublication date
WO2012118750A2 (en)2012-09-07
RU2013140975A (ru)2015-04-10
CA2827859A1 (en)2012-09-07
CN103502472A (zh)2014-01-08
KR20140022815A (ko)2014-02-25
MX2013009662A (es)2014-02-11
US9982302B2 (en)2018-05-29
EP2680884B1 (en)2018-01-17
EP2680884A4 (en)2015-07-08
US20140154247A1 (en)2014-06-05
US20160265056A1 (en)2016-09-15
EP2680884A2 (en)2014-01-08
JP2014512806A (ja)2014-05-29
JP6271254B2 (ja)2018-01-31
BR112013021725A2 (pt)2016-11-01
CN103502472B (zh)2017-06-06
WO2012118750A3 (en)2013-11-14

Similar Documents

PublicationPublication DateTitle
MX353143B (es)Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
IN2012DN02485A (es)
WO2011154139A3 (en)Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
MX2014006158A (es)Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
MX2016005159A (es)Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
EA201301180A1 (ru)Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
JO3766B1 (ar)منشط مستقبل أسيتيل كولين الفا - 7 النيكوتيني
MY188365A (en)Diagnosis and treatments relating to th2 inhibition
PH12014501844A1 (en)Peptidomimetic macrocycles
MY176903A (en)Compounds and methods for kinase modulation, and indications therefor
MX356107B (es)Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
MX351428B (es)Métodos in vitro para correlacionar el nivel de sr2 solubre y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular.
MX2013011098A (es)Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
MX2013009679A (es)Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
MX2013000674A (es)Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
MX2020001160A (es)Anticuerpos y ensayos para la deteccion del receptor 1 de folato.
MX2012001716A (es)Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
PH12014502754A1 (en)Dual receptor antagonistic antigen-binding proteins and uses thereof
TW200637574A (en)Treatment method
MX358541B (es)Metodos para predecir el riesgo de desarrollar hipertension.
MY167920A (en)HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
WO2013160315A3 (en)Genetic predictors of response to treatment with crhr1 antagonists
NZ626242A (en)Anti-asic1 antibodies and uses thereof
MX360774B (es)Antagonistas de progesterona.
BR112015013771A2 (pt)biomarcador preditivo de resposta ao tratamento de ativador do receptor alfa 7 nicotínico de acetilcolina

Legal Events

DateCodeTitleDescription
FGGrant or registration
[8]ページ先頭
©2009-2025 Movatter.jp